Evidence map›Paper›PMID 34371528›Full record

ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2021

[The progress and challenges in immunotherapy for the difficulty- to- treat liver diseases].

J Fan, X Y Mu, X Y Guo, Y T Guo, C Zhen, Y N Song, F S Wang

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

J FanDepartment of Infectious Diseases, the Fifth Medical Center, Chinese PLA General Hospital, Beijing 100039, China National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
X Y MuPeking University 302 Clinical Medical School, Beijing 100039, China National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
X Y GuoCapital Medical University Beijing Ditan Hospital, Beijing 100015, China National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Y T GuoThe Second School of Clinical Medicine Southern Medical University, Guangzhou 510515, China National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
C ZhenDepartment of Infectious Diseases, the Fifth Medical Center, Chinese PLA General Hospital, Beijing 100039, China National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Y N SongDepartment of Infectious Diseases, the Fifth Medical Center, Chinese PLA General Hospital, Beijing 100039, China National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
F S WangDepartment of Infectious Diseases, the Fifth Medical Center, Chinese PLA General Hospital, Beijing 100039, China Peking University 302 Clinical Medical School, Beijing 100039, China Capital Medical University Beijing Ditan Hospital, Beijing 100015, China The Second School of Clinical Medicine Southern Medical University, Guangzhou 510515, China National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Chinese PLA General Hospital · CNNational Clinical Research Center for Digestive Diseases · CNBeijing Ditan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a digestive organ, the liver has the functions of metabolism, synthesis, and detoxification. It is also an immune organ and plays an important role in maintaining anti-infection, autoimmune stability, and anti-tumor. In particular, the liver has unique immunological advantages. Its immune cells can maintain the liver's immune homeostasis and participate in immunoregulation. A variety of immunotherapy is used in clinical trials for the treatment of difficult and critical liver diseases. This review mainly summarizes the recent clinical trials of immunotherapy in chronic hepatitis B, cirrhosis, hepatocellular carcinoma, and autoimmune liver disease.

Indexed as

Carcinoma, HepatocellularHepatitis B, ChronicLiver NeoplasmsHumansImmunotherapyImmuneLiver diseaseTherapeutic

Identifiers

PMID34371528
PMCPMC12813912
OpenAlexW3192953042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.